Wednesday, December 2, 2015

Symic Finds $25M For Biotherapeutics Efforts

San Francisco-based Symic, a biopharmaecuticals company which is developing multiple compounds related to the extracellular matrix (ECM), has raised $25M in a Series A-2 financing. The funding was led by Lilly Ventures, and also included the company's prior investors and other, un-named investors. The company says it has now raised a total of over $43M in funding. Symic, led by Ken Horne, said the funds go towards advancing its pipeline.